John Caswell, MD
Family Medicine · Gentry, ARNPI 1336198365
Payments from drug & device makers
Across 411 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$844
- AbbVie$730
- Amgen$664
- Bayer$558
- GSK$456
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,280100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $1,111 |
| Novo Nordisk | 57 | $844 |
| AbbVie(2 entities) | 40 | $730 |
| Amgen(2 entities) | 32 | $664 |
| Bayer | 33 | $558 |
| GSK | 30 | $456 |
| Pfizer | 28 | $342 |
| Abbott | 18 | $320 |
| Lilly USA, LLC | 15 | $233 |
| Otsuka America Pharmaceutical, Inc. | 10 | $230 |
| Johnson & Johnson | 11 | $227 |
| Boehringer Ingelheim | 13 | $203 |
| Alnylam Pharmaceuticals Inc. | 6 | $158 |
| Dexcom, Inc. | 9 | $141 |
| Merck | 9 | $125 |
| Kowa Pharmaceuticals America, Inc. | 9 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $105 |
| Biohaven Pharmaceuticals, Inc. | 6 | $101 |
| Boston Scientific | 4 | $96 |
| Sanofi-aventis U.S. LLC | 7 | $81 |
| Avanir Pharmaceuticals, Inc. | 5 | $69 |
| Novartis | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Amarin Pharma, Inc. | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Genentech USA, Inc. | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Eisai Inc. | 2 | $22 |
| Phathom Pharmaceuticals, Inc. | 2 | $21 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$240
- AIRSUPRA$129
- FARXIGA$129
- QULIPTA$121
- TRELEGY ELLIPTA$109
How this compares
$7,280 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 121 | $107,480 |
| XareltoRivaroxaban | 75 | $64,419 |
| EliquisApixaban | 66 | $60,957 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 42 | $57,414 |
| MounjaroTirzepatide | 33 | $34,298 |
| OzempicSemaglutide | 39 | $32,036 |
| ProliaDenosumab | 15 | $26,212 |
| FarxigaDapagliflozin Propanediol | 32 | $21,315 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $20,576 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $19,998 |
| JanuviaSitagliptin Phosphate | 25 | $17,361 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $14,729 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $11,846 |
| EntrestoSacubitril/Valsartan | 14 | $11,308 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $10,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $203 | $113,223133 claims |
| Johnson & JohnsonXarelto | $227 | $64,41975 claims |
| PfizerEliquis | $342 | $60,95766 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $81 | $57,41442 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy | $456 | $42,90075 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,111 | $39,97763 claims |
| Lilly USA, LLCMounjaro | $233 | $34,29833 claims |
| Novo NordiskOzempic | $844 | $32,03639 claims |
| AmgenProlia | $664 | $26,21215 claims |
| MerckJanuvia, Janumet | $125 | $23,37536 claims |
| NovartisEntresto | $53 | $11,30814 claims |
| AbbVieLinzess | $730 | $6,00611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Gentry
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.